Last update 01 Nov 2024

R-Pharm International, LLC

Private Company

Overview

Tags

Skin and Musculoskeletal Diseases
Respiratory Diseases
Other Diseases
Fusion protein
Small molecule drug
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Infectious Diseases2
Immune System Diseases2
Endocrinology and Metabolic Disease1
Hemic and Lymphatic Diseases1
Neoplasms1
Top 5 Drug TypeCount
Small molecule drug1
Monoclonal antibody1
Fusion protein1
Top 5 TargetCount
IL-6(Interleukin-6)1
Tubulin1
IL-1β(Interleukin-1 beta)1

Related

3
Drugs associated with R-Pharm International, LLC
Ixabepilone
Target
Tubulin
Mechanism
Tubulin inhibitors
Active Org.
R-Pharm International, LLC [+4]
Originator Org.
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
Active Indication
Breast Cancer [+3]
Inactive Indication
Adenocarcinoma [+28]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date16 Oct 2007
Olokizumab
Target
IL-6
Mechanism
IL-6 inhibitors
Active Org.
R-Pharm International, LLC [+2]
Originator Org.
UCB SAUCB SA
Active Indication
Rheumatoid Arthritis [+2]
Inactive Indication
Crohn Disease [+3]
Drug Highest PhaseNDA/BLA
First Approval Ctry. / Loc.-
First Approval Date-
Goflikicept
Target
IL-1β
Mechanism
IL-1β inhibitors
Active Org.
R-Pharm International, LLC [+3]
Originator Org.
R-Pharm JSC
Active Indication
Idiopathic Recurrent Pericarditis [+6]
Inactive Indication
Inflammation [+6]
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
14
Clinical Trials associated with R-Pharm International, LLC
NCT05432960 / WithdrawnPhase 3
International, Multi-Center, Double-blind, Randomized, Placebo-Controlled, Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)
NCT06440746 / RecruitingPhase 2/3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase 2/3 Study of Efficacy and Safety of Olokizumab in Subjects With Progressive Fibrosing Interstitial Lung Diseases
NCT04246762 / CompletedPhase 1
A Phase 1, Open-label, Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19, and CYP3A4
100 Clinical Results associated with R-Pharm International, LLC
Login to view more data
0 Patents (Medical) associated with R-Pharm International, LLC
Login to view more data
100 Deals associated with R-Pharm International, LLC
Login to view more data
100 Translational Medicine associated with R-Pharm International, LLC
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2 Clinical
1
2
Phase 3 Clinical
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Olokizumab
 ( IL-6 )		Progressive pulmonary fibrosis
More
Phase 3 Clinical
Goflikicept
 ( IL-1β )		Idiopathic Recurrent Pericarditis
More
Phase 3
Ixabepilone
 ( Tubulin )		Ovarian Cancer
More
Phase 2
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free